Global Leukemia Therapeutics Market is Segmented By Cancer Type (Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Others), By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By End-user (Hospitals, Cancer Centers, Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Leukemia Therapeutics Market Overview
The global "leukemia therapeutics market" size is estimated to reach at a high CAGR during the forecast period 2023-2030
Leukemia is a burgeoning blood cancer that forms in the bone marrow and eventually leads to the uncontrolled growth of blood cells. Amid other cancer types, Leukemia is emerging as a life impinging threat globally. The leukemia therapeutics market consists of different therapeutics advised by the physician for the treatment of Leukemia.
Leukemia Therapeutics Market Scope
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Cancer Type, By Therapy, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Leukemia Therapeutics Market Dynamics
The global leukemia therapeutics market growth is driven by the growing burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in the healthcare sector, government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer drive the market growth.
Rising product approval and product launch by the market players is expected to drive the growth in the forecast period
The increasing product approval and product launch by the market players is expected to propel leukemia therapeutics. For instance, in November 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from acute myeloid leukemia (AML). Similarly, in April 2017, Novartis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for midostaurin (Rydapt) for the treatment of adults diagnosed with FLT3-mutated acute myeloid leukemia (AML). Further, in January 2019, the EU approved BLINCYTO (blinatumomab) in patients with Philadelphia chromosome-negative minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. BLINCYTO is the first and only therapy for a minimal residual disease that has been approved by the EU.
Moreover, the rising incidences of cancer are expected to drive market growth over the forecast period. According to the Centre for Disease Control (CDC), around 14.1 million people were diagnosed with cancer in 2012, resulting in approximately 8.2 million fatalities. About 19.3 million new cases of cancer are projected to be diagnosed by 2025.
Side effects & adverse reactions to leukemia therapeutics are likely o hamper the market growth
Despite the advantages of leukemia treatment products, side effects and adverse reactions associated with the drugs include low blood cell counts, infection, graft versus host disease, tumor lysis syndrome and other side effects like mouth ulcers, diarrhea, hair loss, rashes, nausea and vomiting, fatigue, loss of appetite and neuropathy are likely to limit the growth of the market.
Leukemia Therapeutics Market Industry Analysis
Supply Chain Analysis
Opportunities
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.
Leukemia Therapeutics Market Segment Analysis
The targeted therapy drugs segment is expected to hold the largest share in this market segment
Targeted drugs are most widely used owing to their fewer side effects and higher efficacy and success rate as compared to chemotherapy. Owing to these factors, their sales have increased in recent years. For instance, the first FDA-approved immunotherapy for ALL by Novartis registered sales of USD 76 million in 2018 as compared to USD 6 million in 2017. Similarly, the sales for BLINCYTO by Amgen indicated for ALL increased by 37% in the fourth quarter of 2018.
Leukemia Therapeutics Market Geographical Share
North America region holds the largest market share of the global leukemia therapeutics market
The leukemia therapeutics market holds the largest share in the North American region due to the high incidence rate and advancements in leukemia treatment. According to American Cancer Society estimates, there were around 10,920 deaths due to acute myeloid leukemia in the United States in the year 2019. The statistics involve a large percentage of the adult population, and they require proper medical treatment to increase their life expectancy.
In addition, Europe and the Asia Pacific are followed next after North America, owing to a diversified patient pool and emerging economies in these regions.
Leukemia Therapeutics Market Companies and Competitive Landscape
The global leukemia therapeutics market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen, Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis, Sanofi S.A, Incyte Corp, Pfizer Inc, Johnson & Johnson, AstraZeneca plc and Celgene Corporation. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In January 2019, the EU approved BLINCYTO (blinatumomab) in patients with Philadelphia chromosome-negative minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. BLINCYTO is the first and only therapy for a minimal residual disease that has been approved by the EU.
Key Companies to Watch
F. Hoffmann-La Roche Ltd
Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Product Portfolio: The company portfolio includes Gazyva/Gazyvaro (Obinutuzumab) is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva/Gazyvaro is designed to attack and destroy targeted B-cells both directly and together with the body's immune system. Gazyva is marketed as Gazyvaro in the EU and Switzerland.
